Breast cancer drug 'too expensive' for NHS

A drug that can extend the lives of some women with advanced breast cancer has been rejected for NHS use because it is too expensive.

Kadcyal can give patients with HER2-positive breast cancer which has spread to other parts of the body and where initial treatments have failed an additional six months of life.

The National Institute for Health and Care Excellence (Nice) said the drug was too expensive to recommend for widespread use in the health service.

View all 5 updates ›

Row breaks out over price of breast cancer drug

A furious row has broken out between a drugs company and the NHS regulator in England over the price of a new breast cancer treatment.

Kadcyal which is manufactured by Roche Products Limited can give patients with HER2-positive breast cancer an additional six months of life, but the regulator deemed it too expensive.

ITV News correspondent Nina Nannar reports.

More top news